18 February 2020
Nuformix plc
("Nuformix" or "the Company")
Appointment of Dr Karl Keegan
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs today announces the appointment of Dr Karl Keegan to the Board of Nuformix as a Non-Executive Director with immediate effect.
Karl has over 25 years of experience working in senior roles in the life sciences industry. He is currently Chief Executive Officer and Executive Board member at HOX Therapeutics Ltd, a private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes.
Karl spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the
Karl graduated from University College
Dr Dan Gooding, Chief Executive Officer of Nuformix Plc, commented: "I am delighted to welcome Karl to the Nuformix Board. With his extensive experience in strategy, finance, corporate development and capital markets within life sciences, Karl brings a wealth of experience that is highly relevant to Nuformix at this moment as we enter new stages in the development of the Company and our assets."
The Company has entered into an agreement with Karl whereby Karl will be issued with warrants to subscribe for 3,000,000 new ordinary shares of
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer Email: info@nuformix.com
|
+44 (0)1223 627222 |
Novum Securities Limited Jon Belliss / Colin Rowbury |
+44 (0)20 7399 9427 |
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the